Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.69 |
| ▸ | RAB9A | P51151 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.56 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.56 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.56 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | TGM2 | P21980 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29742107 | 1.00 | MAPT (0.69) | MAPTRAB9APOLBCHRNB4CHRNA3 | |
| SCHEMBL13229205 | 0.90 | CHRNB2 (0.63) | MAPTRAB9APOLBCHRNB4CHRNA3 | |
| SCHEMBL29618158 | 0.90 | CHRNB2 (0.63) | MAPTRAB9APOLBCHRNB4CHRNA3 | |
| SCHEMBL4875099 | 0.90 | CHRNB2 (0.63) | MAPTRAB9APOLBCHRNB4CHRNA3 | |
| SCHEMBL2793032 | 0.90 | CHRNB2 (0.63) | MAPTRAB9APOLBCHRNB4CHRNA3 | |
| SCHEMBL17054802 | 0.87 | MAPT (0.68) | MAPTRAB9APOLBCHRNB4CHRNA3 | |
| SCHEMBL23104683 | 0.85 | MAPT (0.63) | MAPTRAB9APOLBCHRNB4CHRNA3 | |
| SCHEMBL13202791 | 0.85 | MAPT (0.68) | MAPTRAB9APOLBCHRNB4CHRNA3 | |
| SCHEMBL1392965 | 0.84 | MAPT (0.89) | MAPTRAB9APOLBCHRNB4CHRNA3 | |
| SCHEMBL23103675 | 0.84 | POLB (0.71) | MAPTRAB9APOLBCHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146042-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2026-05-28 | — | — | US | disclosed |
| US-12606556-B2 | TYK-2 inhibitor | BEONE MEDICINES I GMBH (CH) | 2026-04-21 | — | — | US | disclosed |
| WO-2025235363-A1 | CYCLIN-DEPENDENT KINASE 4 DEGRADERS | BLUEPRINT MEDICINES CORPORATION (US) | 2025-11-13 | — | — | WO | disclosed |
| CN-115003667-B | TYK-2 inhibitors | 百济神州有限公司 | 2025-04-15 | — | — | CN | disclosed |
| US-20240043428-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | ASTEX THERAPEUTICS LTD. (GB) | 2024-02-08 | — | — | US | disclosed |
| WO-2023220640-A1 | CDK PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20230279012-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230159520-A1 | TYK-2 INHIBITOR | BEONE MEDICINES I GMBH (CH) | 2023-05-25 | — | — | US | disclosed |
| US-20230159520-A1 | TYK-2 INHIBITOR | BEONE MEDICINES I GMBH (CH) | 2023-05-25 | — | — | US | disclosed |
| CN-115003667-A | TYK-2 inhibitors | 百济神州有限公司 | 2022-09-02 | — | — | CN | disclosed |
| WO-2011140488-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GILEAD CONNECTICUT, INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011140488-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GILEAD CONNECTICUT, INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| CN-102186856-A | Pyrrolopyrimidines as CDK inhibitors | NOVARTIS AG | 2011-09-14 | — | — | CN | disclosed |
| US-20110152244-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2011-06-23 | — | — | US | disclosed |
| US-20110152244-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2011-06-23 | — | — | US | disclosed |
| EP-2331547-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS CDK INHIBITORS | Novartis AG (CH) | 2011-06-15 | — | — | EP | disclosed |
| US-20100105653-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG | 2010-04-29 | — | — | US | disclosed |
| US-20100105653-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG | 2010-04-29 | — | — | US | disclosed |
| WO-2010020675-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS CDK INHIBITORS | NOVARTIS AG (CH) | 2010-02-25 | — | — | WO | disclosed |
| WO-2010020675-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS CDK INHIBITORS | NOVARTIS AG (CH) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12606556-B2 | TYK-2 inhibitor | TYK2, TXK, JAK1 | MAPT 3485/4885RAB9A 3431/4885POLB 2084/4885 |
| US-20260146042-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK9, CDK6, CDK7 | MAPT 3344/4885RAB9A 1454/4885POLB 837/4885 |
| US-20110152244-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK6, CDK8, CDK7 | MAPT 2945/4885RAB9A 1830/4885POLB 591/4885 |
| US-20240043428-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK6, CDK8, CDK7 | MAPT 2945/4885RAB9A 1830/4885POLB 591/4885 |
| US-20230279012-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | PDXK, BTK, TYK2 | MAPT 2050/4885RAB9A 3689/4885POLB 1976/4885 |
| US-20230159520-A1 | TYK-2 INHIBITOR | TYK2, IRAK2, PTK2B | MAPT 804/4885RAB9A 3713/4885POLB 2307/4885 |
| US-20100105653-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK6, CDK8, CDK7 | MAPT 2945/4885RAB9A 1830/4885POLB 591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.